Considering the strict criteria for the inclusion of patients and the thorough monitoring process preceding controlled trials there might be an even higher risk when unselected RA patients are treated with anti-TNFα agents in daily rheumatologic care. This evidence concerns the gene TNF and rheumatoid arthritis.